In the Journals

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

September 19, 2019
IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the…

In the Journals

Newly diagnosed cases of AS at increased risk for IMIDs, lower risk for RA

September 16, 2019
Newly diagnosed patients with ankylosing spondylitis in Taiwan demonstrate increased risks for multiple immune-mediated inflammatory diseases…

In the Journals

Quarter of axial SpA patients attain inactive disease after 6 months on first TNF inhibitor

September 11, 2019
Among patients with axial spondyloarthritis receiving their first TNF inhibitor, 27% achieve inactive disease, defined by the Ankylosing Spondylitis…

Q&A With Healio Rheumatology

For IBD-associated arthritis, disease control is becoming a team sport

September 6, 2019
Rheumatologists are generally familiar with complicated case patients who require management across specialties. The same goes for…

In the Journals

Drinking alcohol linked to spinal structural damage in axial SpA

August 28, 2019
Alcohol consumption is significantly associated with spinal structural progression in patients with axial spondyloarthritis, according to data…

In the Journals

Follow-up by same physician, injectable drugs linked to better patient experience

August 27, 2019
Consistent follow-up visits with the same physician and treatment with subcutaneous or IV drugs are associated with better patient-reported…

FDA News

FDA expands Taltz approval for ankylosing spondylitis

August 26, 2019
The FDA has extended approval for ixekizumab injection 80 mg/mL to treat adults with ankylosing spondylitis – or radiographic axial…

Feature

Court ruling upholds Enbrel patent claim, blocks biosimilar rivals

August 23, 2019
A U.S. District Court judge has ruled in favor of Amgen in its lawsuit against Novartis’ Sandoz, which claimed patent infringement on its…

In the JournalsPerspective

ACR cautions against mandated biosimilar switching for AS, axSpA

August 22, 2019
Adults with active ankylosing spondylitis despite treatment with a first TNF-inhibitor, as well as those with stable disease receiving an originator…

Cover Story

Lumpers, Splitters, and the Move Toward New Taxonomy for Rheumatology

Healio Rheumatology, August 2019
Historians attribute Philip II of Macedon — father of Alexander the Great — as the source of the motto and political principle known as…

Meeting News

Key clinical features distinguish peripheral, axial spondyloarthritis

August 17, 2019
HILTON HEAD, S.C. — In a duet session focused on spondyloarthritis, Grace Wright, MD, PhD, and Reeti Joshi, MD, detailed the differences…

Feature

Measles resurgence may pose unique threat to patients with inflammatory diseases

August 2, 2019
There have been nearly 1,100 measles cases in the United States in the first half of 2019 — more cases of measles than in any year since the…

In the Journals

TNF-inhibitor tapering as effective as standard dose in axial SpA

July 25, 2019
Mild TNF inhibitor tapering is about as efficacious as the standard dose treatment in achieving inactive disease in patients with axial…

FDA News

FDA approves Hadlima, fourth Humira biosimilar

July 24, 2019
The FDA has approved the fourth biosimilar to adalimumab, adalimumab-bwwd, for all eligible indications of the biologic product, according to a…

Profile

Corrona: Leveraging 'Big Data' for Improved Patient Outcomes

July 19, 2019
Most scientists, by nature and by training, are in one business: Observe a knowledge gap, and fill it. With that in mind, in 2001, the founders of…

In the JournalsPerspective

Peripheral arthritis can occur at any time during new axial SpA

July 3, 2019
Among patients with recent-onset axial spondyloarthritis, 36% reported developing peripheral arthritis at any time during their disease duration…

In the JournalsPerspective

Opioid prescription common in patients with ankylosing spondylitis

June 26, 2019
Opioid use is highly prevalent among patients with ankylosing spondylitis, ranging from 23.5% in patients with commercial insurance using the ICD…

In the Journals

Less than half of patients with AS remain on first TNF inhibitor after 5 years

June 25, 2019
Only 46% of patients with ankylosing spondylitis remain on their first TNF inhibitor after 5 years, with one-third ending up with no anti-rheumatic…

Meeting News

Bimekizumab improved BASDAI response in ankylosing spondylitis

June 21, 2019
Bimekizumab was associated with improved pain and functionality outcomes compared with placebo in a cohort of patients with ankylosing spondylitis…

Feature

Social media opens new avenue to advocacy in rheumatology

June 21, 2019
Political activism is more accessible than ever thanks to the amplification offered by social media, and rheumatologists can use social media —…